We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
-2.21%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$170M
AUM Growth
-$21.4M
(-11%)
Cap. Flow
-$8.68M
Cap. Flow
% of AUM
-5.12%
Top 10 Holdings %
Top 10 Hldgs %
56.85%
Holding
56
New
12
Increased
10
Reduced
12
Closed
16
Avg Time Held
3.7
quarters
Top 10 Avg Time Held
3.3
quarters
Top 20 Avg Time Held
3.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Theravance Biopharma
TBPH
|
+$4.91M |
| 2 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
+$4.73M |
| 3 |
Clearside Biomedical
CLSD
|
+$4.52M |
| 4 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$4.36M |
| 5 |
Blueprint Medicines
BPMC
|
+$2.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
|
+$5.03M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$4.99M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$4.61M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$3.9M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$2.52M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.49% |
| 2 | Miscellaneous | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Abeona Therapeutics
ABEO
$251M
| $1.94M | 1.14% |
16,000
+12,000
| +300% | +$1.88M |
2016 Q3
1 quarter
|
|
27
CytomX Therapeutics
CTMX
$495M
| $1.87M | 1.1% |
170,000
+10,000
| +6% | +$121K |
2016 Q2
2 quarters
|
|
28
DELISTED
Kineta, Inc. Common Stock
KA
| $1.84M | 1.08% |
1,071
-15
| -1% | -$24.5K |
2016 Q2
2 quarters
|
|
29
Harrow
HROW
$1.05B
| $1.8M | 1.06% |
720,000
-495,381
| -41% | -$1.32M |
2014 Q3
9 quarters
|
|
30
DELISTED
Sage Therapeutics
SAGE
| $1.79M | 1.05% |
+35,000
| New | +$1.65M |
2016 Q4
0 quarters
|
|
|
NDRM
31
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $1.73M | 1.02% |
115,000
+16,500
| +17% | +$309K |
2016 Q1
3 quarters
|
|
|
WGBS
32
DELISTED
WaferGen Bio-systems, Inc.
WGBS
| $1.58M | 0.93% |
+320,000
| New | +$1.41M |
2016 Q4
0 quarters
|
|
|
CORI
33
DELISTED
Corium International, Inc.
CORI
| $1.54M | 0.91% |
380,000
-20,000
| -5% | -$99.8K |
2015 Q4
4 quarters
|
|
34
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $1.22M | 0.72% |
+400,000
| New | +$1.46M |
2016 Q4
0 quarters
|
|
|
AKAO
35
DELISTED
Achaogen Inc
AKAO
| $1.04M | 0.61% |
+80,000
| New | +$549K |
2016 Q4
0 quarters
|
|
36
Ocular Therapeutix
OCUL
$1.58B
| $783K | 0.46% |
+93,600
| New | +$726K |
2016 Q4
0 quarters
|
|
|
TRIL
37
DELISTED
Trillium Therapeutics Inc.
TRIL
| $622K | 0.37% |
110,000
-65,000
| -37% | -$647K |
2014 Q4
8 quarters
|
|
38
BioLineRX
BLRX
$10M
| $230K | 0.14% |
417
| – | – |
2013 Q4
12 quarters
|
|
|
AGRX
39
DELISTED
Agile Therapeutics
AGRX
| $85K | 0.05% |
+8
| New | +$112K |
2016 Q4
0 quarters
|
|
40
DELISTED
Affimed
AFMD
| – | – |
-43,000
| Closed | -$1.2M | – |
|
41
Amarin Corp
AMRN
$246M
| – | – |
-35,000
| Closed | -$2.23M | – |
|
42
DELISTED
Assertio
ASRT
| – | – |
-28
| Closed | -$41K | – |
|
43
Indaptus Therapeutics
INDP
$301M
| – | – |
-78
| Closed | -$1.03M | – |
|
44
Ultragenyx Pharmaceutical
RARE
$1.47B
| – | – |
-35,000
| Closed | -$2.48M | – |
|
45
Tenax Therapeutics
TENX
$59.9M
| – | – |
-12
| Closed | -$905K | – |
|
|
GBT
46
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-200,000
| Closed | -$4.61M | – |
|
|
NBRV
47
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| – | – |
-958
| Closed | -$1.69M | – |
|
|
AMAG
48
DELISTED
AMAG Pharmaceuticals
AMAG
| – | – |
-15,000
| Closed | -$368K | – |
|
|
IMMU
49
DELISTED
Immunomedics Inc
IMMU
| – | – |
-1,200,000
| Closed | -$3.9M | – |
|
|
PTLA
50
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-35,000
| Closed | -$795K | – |
|
Similar funds
CFO
PFM
HBCM
HAS
AI
TPA
ZDA
NW
Opaleye Management's Q4 2016 Portfolio in Review
As of Q4 2016, Opaleye Management held 56 positions worth $170M, down 11% from $191M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Opaleye Management withdrew a net $8.68M in Q4 2016, closing 16 positions and reducing 12 holdings. Its most notable exit was CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA), an estimated $5.03M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier, followed by Miscellaneous.
Against the trend, Opaleye Management opened a new position in Theravance Biopharma worth $5.04M.
- Opaleye Management's largest Q4 2016 buy was Theravance Biopharma: 158,200 shares worth $5.04M.
- Opaleye Management added most to Blueprint Medicines in Q4 2016, an estimated $2.86M increase.
- Opaleye Management's biggest Q4 2016 reduction was Tvardi Therapeutics, cutting an estimated $1.78M.
- Opaleye Management fully exited CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) in Q4 2016, selling an estimated $5.03M.
- Opaleye Management's ten largest holdings make up 57% of its $170M portfolio in Q4 2016.
- Opaleye Management opened 12 new positions and closed 16 in Q4 2016.
- Opaleye Management's portfolio value fell 11% quarter-over-quarter to $170M.
Based on Opaleye Management's 13F filing for Q4 2016, filed 21 Feb 2017.